

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Sanofi (Teplizumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
 Diabetes Research and Wellness 	Wales
Foundation	British National Formulary
Diabetes UK	Care Quality Commission
InDependent Diabetes Trust	Department of Health - Northern Ireland
JDRF	Diabetes UK Cymru
Muslim Council of Britain	Healthcare Improvement Scotland
Network of Sikh Organisations	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	 National Association of Primary Care
	 National Pharmacy Association
Healthcare professional groups	NHS Confederation
• 4front	Scottish Medicines Consortium
Association for the Study of Obesity	Welsh Government
Association of British Clinical District and Association Output District and District an	Welsh Health Specialised Services
Diabetologists	Committee
British & Irish Hypertension Society Dritish & Association for Number 1997	Descible community
British Association for Nursing in Cardiovascular Care	Possible comparator companies
	None
British Geriatrics SocietyBritish Heart Foundation	Relevant research groups
D:::10 : (Cochrane Metabolic & Endocrine
British Society for Paediatric Endocrinology & Diabetes	Disorders Group
 Primary Care Diabetes Society 	Genomics England
 Royal College of General Practitioners 	MRC Clinical Trials Unit
 Royal College of Nursing 	National Institute for Health Research
Royal College of Pathologists	The Society for Research in
Royal College of Physicians	Rehabilitation
Royal Pharmaceutical Society	Wellcome Trust
Royal Society of Medicine	
Society for Endocrinology	Associated Public Health groups

Provisional stakeholder list for the evaluation of teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259 Issue date: July 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
TREND DiabetesUK Clinical Pharmacy Association	Public Health WalesUK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259 Issue date: July 2024





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.